



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: **GAULDIE, et al.**

Serial No.: 09/742,892

Group Art Unit: 1635

Filed: 21 DECEMBER 2000

Examiner: SCHNIZER, RICHARD A.

#17/I.D.S

5 Title: **ACNE VACCINE**

INFORMATION DISCLOSURE STATEMENT


The Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In keeping with the duty of candor and good faith owed to the Patent and Trademark Office, Applicants wish to bring the enclosed printed publications and U.S. patent references to the attention of the Examiner.

Applicant respectfully submits that Applicants' claimed invention is patentable over such references. A form PTO-1449 listing these references is attached. It is understood the Office may find additionally relevant material in these or other references

Respectfully submitted,


DENNIS S. FERNANDEZ, ESQ.
Reg. No. 34,160

Date

4/7/02

FERNANDEZ & ASSOCIATES, LLP
PATENT ATTORNEYS
1047 EL CAMINO REAL, SUITE 201
MENLO PARK, CA 94025

(650) 325-4999
(650) 325-1203: FAX
EMAIL: iploft@iploft.com



22877
PATENT TRADEMARK OFFICE

APR 07 2003

PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRADE
Substitute for form 1449/PTO

C mplete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

Attorney Docket Number

ARK-P007

Application Number

US 09/742,892

Filing Date

12-21-2000

First Named Inventor

Gaudie, Jack

Art Unit

1635

Examiner Name

Schnizer, Richard A

RECEIVED
TECH CENTER 1600/2900
APR 14 2003

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
R5	1	TACKET, C.O. et al. Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by gene delivery device. Vaccine. 1999, 17:2826-2829, 17	
R7	2	GRAHAM, F.L. Adenovirus vectors for high-efficiency gene transfer into mammalian cells. Trends Immunology Today. 2000, 426-428, vol. 21	
R3	3	TEBBUTT, S.J. Technology Evaluation: AAV-CFTR vector targeted genetics. Curr. Opin. Mol. Therapy 1999, 524-9; volume 1	
	4	COTTER, M.A. et al. Molecular genetic analysis of herpes virus and their potential use as vectors for gene therapy applications. Curr. Opin. Mol. Ther. 1999, 633-644, vol. 1	
	5	BRODER, C.C. and EARL, P.L. Recombinant vaccinia viruses. Design, generation and isolation. Mol. Biotechnol. 1999, 223-245, vol. 13.	
	6	GABAGLIA, C.R. et al. A single intramuscular injection with an Adenovirus-expressing IL-12 protects BALB/c mice ... J. Immunol. 1999, 753-760, vol. 162	
	7	STEWART AK et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and ... Gene Therapy, 1999, 350-363, vol. 6.	
	8	MISKIN, J.E. et al. Propionibacterium acnes, a resident of lipid-rich human skin, produces a 33 kDa extracellular ... Microbiology, 1997, 1745-1755, vol. 143	
	9	HYNES, W.L. et al. The extracellular hyaluronidase gene (hyla) of Streptococcus pyogenes. FEM Microbiol. Letters 2000, 109-112, vol. 184	
R5	10	OSTANIN, K. et al. Overexpression, site-directed mutagenesis and mechanism of E. coli acid phosphatase. J. Biol. Chem. 1992, 267:22830-6, vol. 267	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	US 09/742,892
Filing Date	12-21-2000
First Named Inventor	Gauldie, Jack
Art Unit	1635
Examiner Name	Schnitzer, Richard A
Attorney Docket Number	ARK-POO1

Sheet 2 of 3

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MS	11	KARVONEN, S.L. et al Delayed hypersensitivity to propionibacterium acnes in patients with severe nodular acne. Dermatology, 1994, 344-9, vol. 189.	
MS	12	HOLLAND, KT et al. Detection of Propionibacterium acnes polypeptides which have stimulated an immune response. Exp. Dermatol., 1993, 12-16, vol. 2	
MS	13	INGHAM, E. et al Antibodies to P. acnes and P. acnes exocellular enzymes in the normal population at ... Br. J. Dermatol., 1987, 805-812, vol. 116.	
MS	14	GRIBBON EM et al Interaction of Propionibacterium acnes with skin lipids in vitro. J. Gen. Microbiol., 1993, 1745-1751, vol. 139.	
	15	KEARNEY, JN et al Correlations between human skin bacteria and skin lipids. Br. J. Dermatol., 1984, 593-99, vol. 110.	
	16	HIGAKI S. et al Anti-lipase activity of Kampof formulations coptidis rhizoma and its alkaloids against Propioni... J. Dermatol., 1996, 310-314, vol. 23	
	17	WATKINS et al Hyaluronidases of Gram-positive bacteria FEMS Microbiol. Letters 2000, 201-207, vol. 183.	
	18	PAMER, EG. Cell-mediated immunity: The role of bacterial protein secretion, 1998, R457-460, vol. 8. Current Biology	
MS	19	GERDTS, V. et al Fetal immunization by a DNA vaccine delivered to the oral cavity. Nature Medicine, 2000, 929-932, vol. 6	
MS	20	BABUK, LA and TIKOO, SK Adenoviruses as vectors for delivering vaccine to mucosal surfaces. J. Biotechnol. 2000, 105-113, vol. 83.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

RECEIVED
APR 14 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Applicati n Numb r	US 09/742,892
Filing Date	12-21-2000
First Named Inv nt r	Gaudie, Jack
Art Unit	1635
Examiner Name	Schnitzer, Richard A
Attorney Docket Number	ARK-POO1

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PS	21	Xiang, Z. et al. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine, 1999, 2003-2008, vol. 17.	
PS	22	Glenn, G.M. et al. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nature Medicine 2000, 1403-1406, vol. 6.	
PS	23	Lewis, P.J. et al. DNA Vaccines: A Review Advances in Virus research 1999, pp129-188, vol 54.	
PS	24	Futzer, B.M. et al. Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression. Proc. Natl. Acad. Sci. USA 1997, 10889-10894, vol 94.	
PS	25	Diehl, L. et al. The role of CD40 in peripheral T cell tolerance and immunity. J. Mol. Med., 2000, 363-371, vol 78.	

RECEIVED
APR 14 2003
TECH CENTER 1600/2000

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.